IFN-α can increase triglyceride levels and induce hepatic steatosis by upregulating the expression level of acyl-CoA synthetase long chain family member 1, which indirectly promotes HBsAg clearance in patients with CHB (129). Here, IFNA2 is linked to fatty liver disease.